Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Analytical Chemistry >  Standard >  Pharmaceutical Impurity Reference Standards >  Paricalcitol

Paricalcitol

Basic information Safety Supplier Related

Paricalcitol Basic information

Product Name:
Paricalcitol
Synonyms:
  • CS-1390
  • PARICALCITOL (10 MG)F0E3030.997MG/MG(AI)
  • PARICALCITOL
  • 19-nor-1alpha,25-dihydroxyvitamin D2
  • (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-Hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
  • Zemplar
  • 1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-
  • Paricalcitol, >=98%
CAS:
131918-61-1
MF:
C27H44O3
MW:
416.65
EINECS:
658-064-6
Product Categories:
  • Vitamin D3 analogs
  • Chiral Reagents
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • 131918-61-1
Mol File:
131918-61-1.mol
More
Less

Paricalcitol Chemical Properties

Boiling point:
564.8±50.0 °C(Predicted)
Density 
1.121±0.06 g/cm3(Predicted)
Flash point:
14℃
storage temp. 
Store at -20°C,unstable in solution, ready to use.
solubility 
DMSO : 100 mg/mL (240.02 mM; Need ultrasonic)Ethanol : 12.5 mg/mL (30.00 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble)
pka
14.34±0.40(Predicted)
form 
Solid
color 
White to off-white
InChIKey
BPKAHTKRCLCHEA-UBFJEZKGSA-N
SMILES
C[C@]12CCC/C(=C\C=C3C[C@@H](O)C[C@H](O)C3)/[C@]1([H])CC[C@]2([H])[C@H](C)/C=C/[C@H](C)C(O)(C)C |&1:1,10,13,16,20,22,26,r|
CAS DataBase Reference
131918-61-1(CAS DataBase Reference)
More
Less

Safety Information

RIDADR 
UN1170 - class 3 - PG 2 - Ethanol, solution
HS Code 
2936299055
Hazardous Substances Data
131918-61-1(Hazardous Substances Data)
More
Less

Paricalcitol Usage And Synthesis

Description

Paricalcitol was launched as Zemplar in the US for the prevention and treatment of secondary hyperthyroidism associated with chronic renal failure. Paricalcitol is a synthetic vitamin D2, namely a novel 1-alpha-hydroxy-19-noranalogue in which the ring A exocyclic methylene group, typical of all vitamin D systems, has been replaced by two hydrogen atoms. Paricalcitol is the first vitamin D analogue marketed for this indication. In patients with chronic renal failure, Paricalcitol appreciably reduced levels of parathyroid hormone (PTH) without a significant difference in the incidence rate for hypercalcemia or hyperphosphatemia when compared with placebo.

Description

Paricalcitol is a synthetic 1,25-dihydroxy vitamin D2 analog. As vitamin D deficiency, associated with chronic kidney disease, leads to an increase in parathyroid hormone (secondary hyperparathyroidism), paricalcitol is used in renal patients to block parathyroid hormone overproduction. Vitamin D deficiency is also a risk factor in cancer, cardiovascular disease, hypertension, and diabetes, and paricalcitol may have applications in those contexts as well.

Chemical Properties

White Solid

Originator

Abbott (US)

Uses

Antihyperparathyriod

Uses

1,25-Dihydroxy vitamin D2 is a potent agonist of the vitamin D receptor. Paricalcitol is a synthetic 1,25-dihydroxy vitamin D2 analog. As vitamin D deficiency, associated with chronic kidney disease, leads to an increase in parathyroid hormone (secondary hyperparathyroidism), paricalcitol is used in renal patients to block parathyroid hormone overproduction. Vitamin D deficiency is also a risk factor in cancer, cardiovascular disease, hypertension, and diabetes, and paricalcitol may have applications in those contexts as well.

Uses

Synthetic analog of vitamin D. Antihyperparathyroid.

Definition

ChEBI: Paricalcitol is a seco-cholestane and a hydroxy seco-steroid. It has a role as an antiparathyroid drug. It is functionally related to a vitamin D2.

brand name

Zemplar (Abbott).

Clinical Use

Vitamin D analogue:
Treatment and prevention of secondary hyperparathyroidism associated with chronic renal failure

Metabolism

Extensively metabolised via hepatic and non-hepatic pathways to form two relatively inactive metabolites. After oral administration of 3 H-paricalcitol, only about 2% of the dose was eliminated unchanged in the faeces, and no parent drug found in the urine.
Approximately 70% of the radioactivity was eliminated in the faeces and 18% was recovered in the urine. Most of the systemic exposure was from the parent drug.

ParicalcitolSupplier

Beijing Jingzi Pharmaceutical Technology Co., Ltd. Gold
Tel
15011485209
Email
17241816@qq.com
Hydragon Pharma Ltd Gold
Tel
021-50215258
Email
market@hypharma.com
Chemvon Biotechnology Co., Ltd Gold
Tel
021-50790412
Email
info@chemvon.com
Hubei wei shi reagent group ltd., company Gold
Tel
027-02759101766 13125137661
Email
2853877621@qq.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com